Innovación en el tratamiento de los Sarcomas de Partes Blandas - page 17

PFS

Academic analysis

Placebo

(n=123)

Pazopanib (n=246)

Median PFS

(months)

1.6

4.6

Hazard ratio

(95% CI)

0.31 (0.24, 0.40);

<0.0001

CI, confidence interval; PFS, progression-free survival

Aprobación feb/2015 en España

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,7,8,9,10,11,12,13,14,15,16 18,19,20,21,22,23,24,25,26,27,...36